OTCMKTS:NVZMY

Novozymes A/S - NVZMY Stock Forecast, Price & News

$60.44

+1.29 (+2.18%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $60.09
▼
$61.14
50-Day Range: $47.06
▼
$60.65
52-Week Range: $45.97
▼
$83.31

Volume: 11,677 shs
Average Volume: 14,495 shs
Market Capitalization: $13.74 billion

P/E Ratio: 32.68
Dividend Yield: 0.92%
Price Target: $406.67

Novozymes A/S MarketRank™ Forecast

Analyst Rating: Hold
1.88 Rating Score
Upside/Downside: 572.8% Upside
$406.67 Price Target
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.53
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 1.75%
From $1.71 to $1.74 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

2.9

Analyst's Opinion

Consensus Rating
Novozymes A/S has received a consensus rating of Hold. The company's average rating score is 1.88, and is based on 2 buy ratings, 3 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $406.67, Novozymes A/S has a forecasted upside of 572.8% from its current price of $60.44.
Amount of Analyst Coverage
Novozymes A/S has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of Novozymes A/S have been sold short.
Short Interest Ratio / Days to Cover
Novozymes A/S has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Novozymes A/S has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Novozymes A/S has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novozymes A/S does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 31.61% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVZMY.

2.5

News and Social Media Coverage

News Sentiment
Novozymes A/S has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Basic Materials companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Novozymes A/S this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added Novozymes A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novozymes A/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.04% of the stock of Novozymes A/S is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Novozymes A/S are expected to grow by 1.75% in the coming year, from $1.71 to $1.74 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novozymes A/S is 32.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.75.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novozymes A/S is 32.68, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 77.24.
Price to Earnings Growth Ratio
Novozymes A/S has a PEG Ratio of 4.78. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novozymes A/S has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novozymes A/S (OTCMKTS:NVZMY) Stock

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

December 8, 2022 | americanbankingnews.com

Novozymes A/S (OTCMKTS:NVZMY) Receives $406.67 Average PT from Brokerages

December 8, 2022 | americanbankingnews.com

Analysts Set Novozymes A/S (OTCMKTS:NVZMY) Price Target at $406.67

December 1, 2022 | americanbankingnews.com

Brokerages Set Novozymes A/S (OTCMKTS:NVZMY) PT at $406.67

November 17, 2022 | finance.yahoo.com

Novozymes Is at the Forefront of Digital R&D, Turning Data Into an Advantage With Benchling R&D Cloud

November 10, 2022 | finance.yahoo.com

Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

November 10, 2022 | finance.yahoo.com

As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

November 3, 2022 | theglobeandmail.com

Pre-Market Brief: Stocks Retreat As Fed Maintains Hawkish Stance

October 24, 2022 | finance.yahoo.com

Biotalys and Novozymes announce successful Evoca™ feasibility study

October 19, 2022 | seekingalpha.com

NVZMY Novozymes A/S

September 20, 2022 | finance.yahoo.com

Catalysing carbon emission cuts at UNGA

August 11, 2022 | msn.com

Novozymes CEO discusses the company's strong first half

August 11, 2022 | seekingalpha.com

Novozymes A/S (NVZMF) CEO Ester Baiget on Q2 2022 Results - Earnings Call Transcript

August 10, 2022 | markets.businessinsider.com

Here's what to expect from Novozymes A-S (B) Un's earnings

July 14, 2022 | finance.yahoo.com

AXTA vs. NVZMY: Which Stock Is the Better Value Option?

June 20, 2022 | finance.yahoo.com

ESI vs. NVZMY: Which Stock Should Value Investors Buy Now?

June 14, 2022 | morningstar.com

Novozymes A/S ADR - Stock Quote NVZMY

June 7, 2022 | finanznachrichten.de

Novozymes A/S: Novozymes extends the lifetime of textiles with sustainable innovation

May 31, 2022 | apnews.com

Industry Leader Novozymes OneHealth’s White Paper on Helicobacter Pylori Research was Officially Released

May 25, 2022 | msn.com

Novozymes CEO: We must stop subsidizing the past

March 31, 2022 | finance.yahoo.com

Novozymes announces plan to increase prices to cover rising cost of raw materials, energy, and logistics

March 17, 2022 | ca.finance.yahoo.com

Novozymes A/S (NVZMY)

February 2, 2022 | reuters.com

Novozymes reports Q4 operating profit below estimates

February 1, 2022 | finance.yahoo.com

Group financial statement and annual report for 2021

February 1, 2022 | finance.yahoo.com

Novozymes delivers strong 2021 full-year results and expects continued, solid progress in 2022

December 10, 2021 | finance.yahoo.com

CE or NVZMY: Which Is the Better Value Stock Right Now?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Company Calendar

Last Earnings: 4/29/2020
Today: 12/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Basic Materials
Current Symbol: OTCMKTS:NVZMY
CUSIP: N/A
CIK: 1131345
Web: www.novozymes.com
Phone: (454) 446-0000
Fax: 45-4446-9999
Employees: 6,527
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $406.67
High Stock Price Forecast: $490.00
Low Stock Price Forecast: $360.00
Forecasted Upside/Downside: +572.8%
Consensus Rating: Hold
Rating Score (0-4): 1.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 32.68
Forward P/E Ratio: 35.35
P/E Growth: 4.78
Net Income: $500.53 million
Net Margins: 20.08%
Pretax Margin: 24.04%
Return on Equity: 27.21%
Return on Assets: 12.95%

Debt

Debt-to-Equity Ratio: 0.31
Current Ratio: 1.20
Quick Ratio: 0.71

Sales & Book Value

Annual Sales: $2.38 billion
Price / Sales: 5.77
Cash Flow: $2.24 per share
Price / Cash Flow: 26.97
Book Value: $8.51 per share
Price / Book: 7.10

Miscellaneous

Outstanding Shares: 227,260,000
Free Float: N/A
Market Cap: $13.74 billion
Optionable: Not Optionable
Beta: 0.68

Social Links

Key Executives

Ms. Ester Baiget (Age 51)
Pres & CEO
Comp: $2.14M

Mr. Lars Green M.Sc. (Age 55)
MSc, Exec. VP & CFO
Comp: $2.09M

Ms. Graziela Chaluppe dos Santos Malucelli (Age 49)
COO and Exec. VP of Operations, Supply & Quality

Mr. Tobias Cornelius Bjorklund
Head of Investor Relations

Mr. Tue Micheelsen
VP of Global Sales & Marketing

Mr. Morten Enggaard Rasmussen (Age 46)
Exec. VP of People, Sustainability & Brand

Mr. Pedro Luiz Fernandes
Head of Corp. Affairs & Sustainability - Novozymes Latin America

Mr. Anders Lund (Age 49)
Exec. VP of Consumer Biosolutions

Mr. Sebastian Søderberg
VP and Head of New Bus. Devel. - Incubations & Acquisitions

Ms. Tina Sejersgaard Fanoe (Age 53)
Exec. VP of Agriculture & Industrial Biosolutions

Key Competitors

View All Competitors

NVZMY Stock - Frequently Asked Questions

Should I buy or sell Novozymes A/S stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVZMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View NVZMY analyst ratings or view top-rated stocks.
What is Novozymes A/S's stock price forecast for 2023?: 8 Wall Street analysts have issued 12-month price objectives for Novozymes A/S's stock. Their NVZMY share price forecasts range from $360.00 to $490.00. On average, they anticipate the company's stock price to reach $406.67 in the next twelve months. This suggests a possible upside of 572.8% from the stock's current price.
View analysts price targets for NVZMY or view top-rated stocks among Wall Street analysts.
How have NVZMY shares performed in 2022?: Novozymes A/S's stock was trading at $83.12 at the beginning of 2022. Since then, NVZMY stock has decreased by 27.3% and is now trading at $60.44.
View the best growth stocks for 2022 here.
Are investors shorting Novozymes A/S?: Novozymes A/S saw a increase in short interest in October. As of October 31st, there was short interest totaling 1,200 shares, an increase of 100.0% from the October 15th total of 600 shares. Based on an average daily volume of 38,700 shares, the short-interest ratio is currently 0.0 days.
View Novozymes A/S's Short Interest.
How were Novozymes A/S's earnings last quarter?: Novozymes A/S (OTCMKTS:NVZMY) posted its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, hitting the consensus estimate of $0.42. The biotechnology company earned $558.75 million during the quarter. Novozymes A/S had a net margin of 20.08% and a trailing twelve-month return on equity of 27.21%.
How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?: Novozymes A/S declared a dividend on Tuesday, March 15th. Shareholders of record on Friday, March 18th will be paid a dividend of $0.567 per share on Tuesday, April 5th. This represents a yield of 0.95%. The ex-dividend date is Thursday, March 17th.
Read our dividend analysis for NVZMY.

Is Novozymes A/S a good dividend stock?: Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.55 per share and currently has a dividend yield of 0.92%.
Read our dividend analysis for NVZMY.
What is Novozymes A/S's stock symbol?: Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."
How do I buy shares of Novozymes A/S?: Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novozymes A/S's stock price today?: One share of NVZMY stock can currently be purchased for approximately $60.44.
How much money does Novozymes A/S make?: Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $13.74 billion and generates $2.38 billion in revenue each year.
How many employees does Novozymes A/S have?: The company employs 6,527 workers across the globe.
Does Novozymes A/S have any subsidiaries?: The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.
Read More
How can I contact Novozymes A/S?: Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.

This page (OTCMKTS:NVZMY) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial